Retatrutide cuts weight up to 20.8% in phase III diabetes trial TRIUMPH-2
HbA1c fell as much as 1.50% from baseline on top of background therapy, with up to 40% of treated participants reaching normoglycemia.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 2 03:00 ETSource: MedPage Today
The wire
- 01In TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes took retatrutide for 80 weeks; the efficacy estimand showed 20.8% weight loss at the highest dose versus placebo.
- 02Results, presented at EASD and published in The Lancet, exceed prior diabetes-population figures of 13.2% with high-dose semaglutide and 15.7% with tirzepatide.
- 03Weight loss still trailed the 28.3% seen in TRIUMPH-1 in people without diabetes; the unapproved triple agonist already has a gray market, and Lilly sponsored the trial.
From the source
Read at medpagetoday.comRetatrutide Delivers Substantial Weight Loss in Type 2 Diabetes
The investigational triple agonist retatrutide substantially improved glycemic control and body weight in adults with obesity and type 2 diabetes, a phase III trial showed.
